Accendra Health vs ePlus
ACH and PLUS side by side, both in professional and commercial equipment and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACH and PLUS compare
ePlus is the larger company, worth 124 times as much as Accendra Health ($2.4B against $19.5M).
ePlus grew revenue faster over the last twelve months (16.5% versus −3.3% for Accendra Health).
ePlus keeps more of each dollar of sales as profit, with a net margin of 5.1% compared with −11.4% at Accendra Health.
ePlus pays a dividend yielding 1.1%; Accendra Health does not pay one.
ePlus scores higher on the StockData Score (15 against 4 for Accendra Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACH | PLUS |
|---|---|---|
| Size and price | ||
| Market cap | $19.5M | $2.4B |
| Share price | $0.254 | $92.91 |
| Change, 1 year | −95.1% | 28.3% |
| Change, 5 years | −99.4% | 51.8% |
| Beta (5Y) | 1.46 | 0.98 |
| Employees | 6,500 | 2,148 |
| StockData Score | ||
| Total score | 4 | 15 (better) |
| Valuation score | 4 (better) | 2 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 4 (better) |
| Health score | 0 | 6 (better) |
| Dividend score | 0 | 2 (better) |
| Valuation | ||
| P/E | – | 19.5× |
| P/S | 0.0× (better) | 1.0× |
| P/B | – | 2.3× |
| EV/EBITDA | 6.1× (better) | 10.1× |
| PEG | – | 4.96 |
| FCF yield | −1827% | – |
| Fair value | $12.26 | $84.59 |
| Margin of safety | 97.9% (better) | −9.8% |
| Growth | ||
| Revenue growth (TTM) | −3.3% | 16.5% (better) |
| Revenue growth, 5Y average | −20.1% | 9.3% (better) |
| Net income growth (TTM) | – | 4.5% |
| EPS growth (TTM) | – | 5.5% |
| EPS growth, 5Y average | – | 12.7% |
| Profitability | ||
| Gross margin | 44.8% (better) | 25.2% |
| Operating margin | 1.1% | 6.9% (better) |
| Net margin | −11.4% | 5.1% (better) |
| FCF margin | −13.5% | – |
| Return on equity | – | 12.0% |
| Return on invested capital | 1.6% | 20.7% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Net debt / EBITDA | 5.99 | – |
| Interest coverage | 0.2× | – |
| Current ratio | 0.41 | 2.13 (better) |
| Altman Z-score | 0.30 | 4.69 (better) |
| Piotroski F-score | 2 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 1.1% |
| Payout ratio | – | 21.3% |
| Years of dividend growth | – | 0 |
| Buyback yield | – | 2.0% |
| Shareholder yield | 0.00% | 3.1% (better) |
| Ownership | ||
| Held by institutions | 81.1% | 96.6% |
| Held by insiders | 21.0% | 2.1% |
| Insider net buying, 12 months | – | −$1.6M |
| Short interest, % of float | 13.9% | 5.4% |
Go deeper
- ACH stock overview
- ACH income statement
- ACH valuation and score
- PLUS stock overview
- PLUS income statement
- PLUS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.